Inhibitors that have previously made it to clinical trials for MM have been pan-PIM inhibitors with varying degrees of efficacy in targeting each isoform.4, 8 In this study, we sought to elucidate the differential roles of each of the PIM isoforms, and in so doing, gain a better understanding of what mode of targeting would be most relevant to the treatment of MM. The gene discussed is PIM1; the disease is Miyoshi myopathy.